AU2016224503A1 — Solid preparation
Assigned to Takeda Pharmaceutical Co Ltd · Expires 2017-09-14 · 9y expired
What this patent protects
Provided are: a solid preparation which improves the stability of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethyl amino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-yl)phenyl)-N'-methoxyurea and a salt thereof which are present in the solid …
USPTO Abstract
Provided are: a solid preparation which improves the stability of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethyl amino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-6-yl)phenyl)-N'-methoxyurea and a salt thereof which are present in the solid preparation; and a method for stabilizing the compound in the solid preparation. A tablet containing the compound in an amount equal to at least 25 mass%; a solid preparation containing (1) the compound, and (2) a low-melting-point oil/fat-like substance selected from polyethylene glycol, glyceryl monostearate, and triethyl citrate; a method for stabilizing the compound present in the tablet and characterized by formulating the compound in an amount equal to at least 25 mass%; and a method for stabilizing the compound and characterized by formulating a low-melting-point oil/fat-like substance selected from polyethylene glycol, glyceryl monostearate, and triethyl citrate in a solid preparation containing the compound.
Drugs covered by this patent
- Orgovyx (relugolix) · MYOVANT SCIENCES
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.